NO20081014L - Sammensetninger - Google Patents

Sammensetninger

Info

Publication number
NO20081014L
NO20081014L NO20081014A NO20081014A NO20081014L NO 20081014 L NO20081014 L NO 20081014L NO 20081014 A NO20081014 A NO 20081014A NO 20081014 A NO20081014 A NO 20081014A NO 20081014 L NO20081014 L NO 20081014L
Authority
NO
Norway
Prior art keywords
compounds
compositions
agonists
activity
formula
Prior art date
Application number
NO20081014A
Other languages
English (en)
Other versions
NO340489B1 (no
Inventor
Geoffrey Stemp
Mervyn Thompson
Christopher Norbert Johnson
David Timothy Macpherson
Steven James Stanway
Susan Marie Westaway
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515381A external-priority patent/GB0515381D0/en
Priority claimed from GB0611469A external-priority patent/GB0611469D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of NO20081014L publication Critical patent/NO20081014L/no
Publication of NO340489B1 publication Critical patent/NO340489B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Foreliggende oppfinnelse angår nye benzylpiperazinderivater slik som forbindelser med forrnel (I), som har aktivitet som agonister av GPR38-reseptoren og anvendelsen av slike forbindelser eller farmasøytiske sammensetninger derav ved behandling av gastrointestinale forstyrrelser.
NO20081014A 2005-07-26 2008-02-26 Nye benzylpiperazinderivater, fremgangsmåter for deres fremstilling og anvendelse ved behandling av gastrointestinale forstyrrelser NO340489B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0515381A GB0515381D0 (en) 2005-07-26 2005-07-26 Compounds
GB0611469A GB0611469D0 (en) 2006-06-09 2006-06-09 Compounds
PCT/EP2006/007390 WO2007012479A2 (en) 2005-07-26 2006-07-24 Benzylpiperazine derivates and their medical use

Publications (2)

Publication Number Publication Date
NO20081014L true NO20081014L (no) 2008-04-10
NO340489B1 NO340489B1 (no) 2017-05-02

Family

ID=37560776

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081014A NO340489B1 (no) 2005-07-26 2008-02-26 Nye benzylpiperazinderivater, fremgangsmåter for deres fremstilling og anvendelse ved behandling av gastrointestinale forstyrrelser

Country Status (29)

Country Link
US (2) US8536182B2 (no)
EP (2) EP1907374B1 (no)
JP (1) JP4938777B2 (no)
KR (1) KR101281435B1 (no)
AR (1) AR054508A1 (no)
AU (1) AU2006274212B2 (no)
BR (1) BRPI0613987A2 (no)
CA (1) CA2616513C (no)
CR (1) CR9722A (no)
CY (1) CY1113257T1 (no)
DK (1) DK1907374T3 (no)
EA (1) EA014061B1 (no)
EG (1) EG26235A (no)
ES (1) ES2390812T3 (no)
HK (1) HK1116477A1 (no)
HR (1) HRP20120833T1 (no)
IL (1) IL188854A (no)
JO (1) JO2747B1 (no)
MA (1) MA29723B1 (no)
MX (1) MX2008001211A (no)
MY (1) MY150098A (no)
NO (1) NO340489B1 (no)
NZ (1) NZ565062A (no)
PE (1) PE20070180A1 (no)
PL (1) PL1907374T3 (no)
PT (1) PT1907374E (no)
SI (1) SI1907374T1 (no)
TW (1) TWI376375B (no)
WO (1) WO2007012479A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
US8536182B2 (en) * 2005-07-26 2013-09-17 Glaxo Group Limited Benzylpiperazine derivatives and their medical use
GB0524814D0 (en) * 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
ATE486605T1 (de) 2006-01-27 2010-11-15 Ms Science Corp Piperidin- und piperazin-derivate
JP5028484B2 (ja) * 2006-06-28 2012-09-19 グラクソ グループ リミテッド Ｇｐｒ３８受容体媒介疾患の治療に有用なピペラジニル誘導体
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds
CA2750699C (en) 2009-02-27 2015-12-29 Raqualia Pharma Inc. Oxyindole derivatives with motilin receptor agonistic activity
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
CN113292485B (zh) * 2021-06-08 2023-10-27 河南大学 苄基哌嗪脲类trpv1拮抗和mor激动双靶点药物及制备方法和应用

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5385912A (en) * 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
TW355711B (en) 1992-11-04 1999-04-11 Chugai Pharmaceutical Co Ltd Erythromycin derivatives
JP3449766B2 (ja) 1993-11-19 2003-09-22 中外製薬株式会社 モチリンアンタゴニスト
US5593994A (en) * 1994-09-29 1997-01-14 The Dupont Merck Pharmaceutical Company Prostaglandin synthase inhibitors
JP3901239B2 (ja) 1996-03-13 2007-04-04 大正製薬株式会社 アリールアルカン誘導体
US5965578A (en) * 1996-04-03 1999-10-12 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5734012A (en) * 1996-05-16 1998-03-31 Ohmeda Pharmaceutical Products Division Inc. Cyclic motilin-like polypeptides with gastrointestinal motor stimulating activity
DE19644195A1 (de) * 1996-10-24 1998-04-30 Solvay Pharm Gmbh 10,13,15-Trioxatricyclo[9.2.1.1.·9·.·6·]-pentadecanon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6100239A (en) * 1996-11-26 2000-08-08 Chugai Seiyaku Kabushiki Kaisha 13-membered ring macrolide compound, medicine containing the same, and process for producing the same
US6060491A (en) * 1997-06-19 2000-05-09 Dupont Pharmaceuticals 6-membered aromatics as factor Xa inhibitors
JP3583928B2 (ja) * 1997-08-15 2004-11-04 中外製薬株式会社 フェネチルアミン誘導体
US5972939A (en) * 1997-10-28 1999-10-26 Ortho-Mcneil Pharmaceutical, Inc. Cyclopentene derivatives useful as antagonists of the motilin receptor
DE19805822B4 (de) 1998-02-13 2009-02-05 Solvay Pharmaceuticals Gmbh 11-Acetyl-12,13-dioxabicyclo[8.2.1]tridecenon-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US6165985A (en) 1998-02-13 2000-12-26 Solvay Pharmaceuticals Gmbh 11-acetyl-12,13-dioxabicyclo[8.2.1]-tridecenone derivatives, processes for their preparation and pharmaceutical compositions comprising them
GB9804734D0 (en) * 1998-03-05 1998-04-29 Pfizer Ltd Compounds
ATE354582T1 (de) * 1998-06-12 2007-03-15 Merck & Co Inc Klonierung und identifizierung des motilin- rezeptors
JP2000191700A (ja) * 1998-12-28 2000-07-11 Kyowa Hakko Kogyo Co Ltd 持続型消化管運動ペプチド
US20020052380A1 (en) * 2000-02-18 2002-05-02 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
US20020010184A1 (en) * 2000-02-18 2002-01-24 Dinsmore Christopher J. Inhibitors of prenyl-protein transferase
AU2001247357A1 (en) * 2000-03-13 2001-09-24 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclobutene derivatives useful as antagonists of the motilin receptor
US6423714B2 (en) * 2000-03-13 2002-07-23 Ortho Mcneil-Pharmaceutical, Inc.. Cyclohexene derivatives useful as antagonists of the motilin receptor
WO2001068620A1 (en) 2000-03-13 2001-09-20 Ortho-Mcneil Pharmaceutical, Inc. Novel cyclopentene derivatives useful as antagonists of the motilin receptor
US6511980B2 (en) * 2000-05-05 2003-01-28 Ortho Mcneil Pharmaceutical, Inc. Substituted diamine derivatives useful as motilin antagonists
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
EP1392679B1 (de) 2001-05-10 2005-11-02 Solvay Pharmaceuticals GmbH Neue 1-amidomethylcarbonyl-piperidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US6977264B2 (en) * 2001-07-25 2005-12-20 Amgen Inc. Substituted piperidines and methods of use
PA8575901A1 (es) 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
US7223788B2 (en) * 2003-02-14 2007-05-29 Sanofi-Aventis Deutschland Gmbh Substituted N-aryl heterocycles, process for their preparation and their use as medicaments
PL1648922T3 (pl) * 2003-07-31 2011-05-31 Tranzyme Pharma Inc Przestrzennie określone związki makrocykliczne użyteczne w dziedzinie odkrywania leków
US7407941B2 (en) * 2003-08-26 2008-08-05 Pfizer, Inc. N-desmethyl-N-substituted-11-deoxyerythromycin compounds
US7338954B2 (en) 2003-09-17 2008-03-04 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
US7262195B2 (en) * 2003-09-17 2007-08-28 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
JPWO2005063720A1 (ja) 2003-12-25 2007-07-19 日本新薬株式会社 アミド誘導体及び医薬
WO2005077345A1 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Compounds for the treatment of gastro-esophageal reflux disease
WO2005077368A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
WO2005077373A2 (en) 2004-02-03 2005-08-25 Astrazeneca Ab Treatment of gastro-esophageal reflux disease (gerd)
EP1732549A4 (en) * 2004-03-18 2009-11-11 Brigham & Womens Hospital METHOD FOR THE TREATMENT OF SYNUCLEINOPATHIES
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
US20050272722A1 (en) * 2004-03-18 2005-12-08 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20050277629A1 (en) * 2004-03-18 2005-12-15 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
CA2559221A1 (en) * 2004-03-18 2005-09-29 Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
PE20060315A1 (es) 2004-05-24 2006-05-15 Irm Llc Compuestos de tiazol como moduladores de ppar
SE0401345D0 (sv) 2004-05-25 2004-05-25 Astrazeneca Ab Therapeutic compounds: Pyridine as scaffold
GB0611907D0 (en) 2006-06-15 2006-07-26 Glaxo Group Ltd Compounds
JP2009501199A (ja) * 2005-07-12 2009-01-15 グラクソ グループ リミテッド Ｇｐｒ３８アゴニストとしてのピペラジンヘテロアリール誘導体
US8536182B2 (en) * 2005-07-26 2013-09-17 Glaxo Group Limited Benzylpiperazine derivatives and their medical use
GB0524814D0 (en) 2005-12-05 2006-01-11 Glaxo Group Ltd Compounds
JP5028484B2 (ja) 2006-06-28 2012-09-19 グラクソ グループ リミテッド Ｇｐｒ３８受容体媒介疾患の治療に有用なピペラジニル誘導体
GB0723317D0 (en) 2007-11-28 2008-01-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
KR20080037663A (ko) 2008-04-30
PT1907374E (pt) 2012-11-05
MY150098A (en) 2013-11-29
PE20070180A1 (es) 2007-04-25
PL1907374T3 (pl) 2012-12-31
TW200745081A (en) 2007-12-16
MA29723B1 (fr) 2008-09-01
AU2006274212B2 (en) 2011-06-09
EA200800421A1 (ru) 2008-06-30
IL188854A0 (en) 2008-04-13
US20090054456A1 (en) 2009-02-26
EP1907374A2 (en) 2008-04-09
NO340489B1 (no) 2017-05-02
TWI376375B (en) 2012-11-11
ES2390812T3 (es) 2012-11-16
NZ565062A (en) 2011-02-25
DK1907374T3 (da) 2012-10-15
EA014061B1 (ru) 2010-08-30
HRP20120833T1 (hr) 2012-11-30
SI1907374T1 (sl) 2012-11-30
US8536182B2 (en) 2013-09-17
AR054508A1 (es) 2007-06-27
IL188854A (en) 2013-08-29
EG26235A (en) 2013-05-07
CY1113257T1 (el) 2016-04-13
JP4938777B2 (ja) 2012-05-23
KR101281435B1 (ko) 2013-07-02
JP2009502842A (ja) 2009-01-29
HK1116477A1 (en) 2008-12-24
EP2441763A1 (en) 2012-04-18
US20130317041A1 (en) 2013-11-28
AU2006274212A1 (en) 2007-02-01
JO2747B1 (en) 2014-03-15
MX2008001211A (es) 2008-03-24
WO2007012479A2 (en) 2007-02-01
CR9722A (es) 2008-04-10
BRPI0613987A2 (pt) 2011-03-01
CA2616513C (en) 2013-02-19
CA2616513A1 (en) 2007-02-01
EP1907374B1 (en) 2012-08-22
WO2007012479A3 (en) 2007-04-26

Similar Documents

Publication Publication Date Title
NO20081014L (no) Sammensetninger
ATE474834T1 (de) Als agonisten des gpr38-rezeptors geeignete biarylverbindungen
NO20076460L (no) Nye fluorenderivater, sammensetninger inneholdende nevnte derivater og anvendelse derav
NO20090266L (no) Piperazinylderivater anvendelige i behandlingen av GPR38 receptormedierte sykdommer
NO20082124L (no) Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom
NO20074634L (no) Substituerte heterocykler og deres anvendelse som CHK1-, PDK1- og PAK-inhibitorer
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20083214L (no) Pyrimidinylarylurea-derivater som omdannes til FGF-inhibitorer
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20090783L (no) Pyrimidonforbindelser som inhibitorer av GSK-3
NO20065984L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20081893L (no) 4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20082090L (no) Pyridopyrimidinoninhibitorer av P13K alfa
NO20063449L (no) Substituerte heterocykler og deres anvendelse
NO20076059L (no) 2,4-Diamino-pyrimidiner anvendt som aurorainhibitorer
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20065983L (no) Forbindelser og sammensetninger som PPAR modulatorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
NO20063748L (no) Kinolinderivater og anvendelse derav som mykobakterielle inhibitorer
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20084489L (no) Azolopyrimidiner som inhibitorer av cannabinoid 1 aktivitet
NO20070487L (no) 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer.
ATE542795T1 (de) Benzylpiperazinderivate als motilin- rezeptorantagonisten

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: GLAXO GROUP LTD, GB

MM1K Lapsed by not paying the annual fees